Fluoxymesterone
Fluoxymesterone is an oral male hormone approved in 1956 and once used to palliate advanced breast cancer in women, an approach abandoned when better tolerated antioestrogens and aromatase inhibitors arrived.
Overview
Androgens were among the first hormonal treatments for breast cancer, and fluoxymesterone, a potent oral androgen approved in the United States in 1956, carried a labelled indication for palliation of androgen-responsive recurrent breast cancer in women one to five years past the menopause. Virilisation, liver toxicity and fluid retention limited it, and by the 1980s tamoxifen and then the aromatase inhibitors had replaced androgen therapy. The drug has been discontinued in most markets, but androgen receptor biology in breast cancer is again under study with newer agents such as enobosarm.
A 17-alpha-alkylated testosterone derivative that activates the androgen receptor; in breast cancer it opposes oestrogen-driven growth and suppresses gonadotrophins. Connects to Androgen receptor.
1.Fluoxymesterone slips into a pocket on Androgen receptor.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 1956 | Palliation of androgen-responsive advanced breast cancer in postmenopausal women (historic label) |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Fluoxymesterone" OR ABSTRACT:"Fluoxymesterone" OR TITLE:"Halotestin" OR ABSTRACT:"Halotestin" OR TITLE:"Androxy" OR ABSTRACT:"Androxy") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Fluoxymesterone, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentDiethylstilbestrol
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag chembl-universe.
- TreatmentFormestane
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag chembl-universe.
- TreatmentAminoglutethimide
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag chembl-universe.
- TreatmentTechnetium Tc-99m sulfur colloid
Shares HR-positive / HER2-negative breast cancer and the tag chembl-universe.
- TreatmentHistrelin
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag chembl-universe.
- TreatmentAbarelix
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag chembl-universe.
- TreatmentBuserelin
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag chembl-universe.
- TreatmentDoxifluridine
Shares HR-positive / HER2-negative breast cancer and the tag chembl-universe.